UAB Sicor Biotech
[US -- Symbol : Private] V.A. Graiciuno Street 8, Vilnius,LT-02241,Lithuania email: [email protected] Website: http://www.sicor.lt phone: 370-5-266-0203 Industry Classification: Pharmaceuticals and Healthcare-->Biotechnology
Business Summary : UAB Sicor Biotech is a biotechnology company that develops and manufactures recombinant biopharmaceuticals. It is a member of Teva Group. The company's strategic aim is to expand the existing markets and penetrate into the markets of industrial countries with new alternative biological pharmaceuticals. It was acquired by Teva Parenteral Medicines, Inc. (formerly Sicor, Inc.) in 2004. SICOR Biotech's GMP-compliant pilot plant is dedicated to process development and clinical sample production of both bacterial and mammalian cell culture-derived products (scale 10 l fermentation for bacterial and 2 l fermentation for mammalian cells, and up to 200 mg protein per cycle). It manufactures three main products which include: active pharmaceutical substances like- interferon alfa-2b, granulocyte colonies stimulating factor (G-CSF) and somatropin (hGH). The company also offers prescription and non prescription drugs categories which include: Respiratory system, Genitourinary, Digestive systems, Food additives, Antiparasitic, Blood and blood drugs, Immunosuppressant, oncology, Nervous system etc. Its products include: Vaistai Nosies Ligoms Gydyti, Stoptussin Fyto 100ml, Peponen 300mg caps. N91, Nittyfor tirpalas 60ml, Antianeminiai Vaistai, Ferroplex drag N100, Paclitaxel-Teva 30 mg, N.1 inj., Etoposide - Teva 20mg/ml 5 ml sol. for inf. N.1 etc.
1 LSA. Life Science Analytics, Inc. 2011
TABLE OF CONTENTS
MANAGEMENT PROFILE .............................................................................................................................. 3 RECENT UPDATES ....................................................................................................................................... 4 News Category: Company Announcements............................................................................................... 4 News Category: Deals & Alliances ............................................................................................................. 4 News Category: Mergers & Acquisitions .................................................................................................... 4
2 LSA. Life Science Analytics, Inc. 2011
MANAGEMENT PROFILE
Arunas Vaitkevicius -- Chief Technologist and Chief Engineer -Vladas Algirdas Bumelis -- Managing Director -Ale Leonaviciene -- Head of Quality -Chamomile Rukiene -- Group Manager, Regulation Affairs -Giedrius Zunda -- Manager, Production --
3 LSA. Life Science Analytics, Inc. 2011
RECENT UPDATES
Company Announcements 3/1/2008 -- Ananda Rajah appointed CEO and executive director On March 1, 2008 Atos Wellness, Ltd. announced that Ananda Rajah appointed CEO and executive director with a salary of $1.00 plus 5 million options at 12, 18 and 24 cents providing company reaches $2 million EBIDTA for year 30th June 2009. 7/1/2002 -- Medec formed as an Australian Public Company On July 1, 2002 Atos Wellness, Ltd. announced that Medec formed as an Australian Public Company on 13 May 2002 to consolidate several developing medical technology interests into a viable international business.
Deals & Alliances 4/14/2008 -- Atos Wellness forms joint venture with Sol Wellness On April 14, 2008 ATOS Wellness Limited announced that it has formed a joint venture with SOL Wellness Pty Ltd to establish up to 12 new Wellness Centres throughout Australia. In this joint venture Atos Sol Wellness will own and operate the aquatic, wellness centre, day spa and weight management businesses within the new community centres using the ATOS inspired life, body contours and bodycure models. The existing ATOS Inspired Life Centre in Bentley, Western Australia, with its swimming pool, fitness centre, body contours day spa, bodycure weight management and physiotherapy services will be the model for the new joint venture company. The new company's operations begin.
Mergers & Acquisitions 7/30/2010 -- Calzada agrees to vend Metabolic into ATOS Wellness On July 30, 2010 The Board of Directors of Calzada Ltd announced that it has signed an agreement with ATOS Wellness Ltd under which Calzada will invest $500,000 cash and vend into ATOS its 100% owned subsidiary Metabolic Pharmaceuticals Pty Ltd, plus all intellectual property associated with Metabolic's drug development assets, primarily focused on AOD9604. 1/1/2008 -- Medec Ltd merges with Atos Wellness Group On January 1, 2008 Atos Wellness, Ltd. announced that Medec Ltd merges with Atos Wellness Group out of Singapore and is renamed Atos Wellness Ltd Ananda receives 97 million shares at 12 cents per share (Even though shares are trading below 6 cents) as consideration for the sales of Atos Wellness Group into Medec. Ananda guarantees S$2.5million EBIDTA profit per year for the next 3 years or his consideration of shares in escrow would be proportionately reduced. 7/1/2006 -- Medec Ltd acquires 51% of Body Contours Singapore On July 1, 2006 Atos Wellness, Ltd. announced that Medec Ltd acquires 51% of Body Contours Singapore. Ananda takes 75% of his consideration by way of 4.5million shares at 30cps.
4 LSA. Life Science Analytics, Inc. 2011
